Attenuation of intestinal absorption by major efflux transporters: Quantitative tools and strategies using a Caco-2 model

Drug Metabolism and Disposition

Volumn 39, Issue 2, 2011, Pages 265-274

  Lin, Xuena ^a   Skolnik, Suzanne ^a   Chen, Xiaohui ^a   Wang, Jianling ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMPRENAVIR; BREAST CANCER RESISTANCE PROTEIN; CETIRIZINE; CHLOROQUINE; CLARITHROMYCIN; COLCHICINE; DACTINOMYCIN; DAUNORUBICIN; DIGOXIN; DOMPERIDONE; EMETINE; ERYTHROMYCIN; ETOPOSIDE; FEXOFENADINE; FLUCONAZOLE; GLYCOPROTEIN P; INDINAVIR; IVERMECTIN; LABETALOL; LOPERAMIDE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 2; NELFINAVIR; PACLITAXEL; RITONAVIR; SAQUINAVIR; SUMATRIPTAN; TACROLIMUS; UNINDEXED DRUG;

ARTICLE; CELL STRAIN CACO 2; CHEMICAL PARAMETERS; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG EXPOSURE; DRUG PENETRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADENOSINE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHROMATOGRAPHY, LIQUID; DIBENZOCYCLOHEPTENES; DRUG DISCOVERY; HUMANS; INTESTINAL ABSORPTION; MASS SPECTROMETRY; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; P-GLYCOPROTEINS; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; PROPIONATES; QUINOLINES; SUBSTRATE SPECIFICITY;

EID: 79251520336     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034629     Document Type: Article

References (40)

1. Adachi Y, Suzuki H, and Sugiyama Y (2003) Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm Res 20:1163-1169.
2. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, and Schinkel AH (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417-425.
3. 9 tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein. Addict Biol 13:295-300.
4. Chen C, Lin J, Smolarek T, and Tremaine L (2007) P-Glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos 35:1725-1729.
5. Chen C, Liu X, and Smith BJ (2003) Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Metab 4:272-291.
6. Choudhuri S and Klaassen CD (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25:231-259. (Pubitemid 44034685)
7. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, and Starling JJ (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171-4179.
8. Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, and Farinotti R (1999) Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates. Br J Pharmacol 127:1728-1734.
9. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, Dörje F, Mürdter TE, Ackermann A, Dormann H, et al. (2007) Role of P-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 46:1039-1049.
10. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, and Lee CA (2009) Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173-181.
11. Gekeler V, Ise W, Sanders KH, Ulrich WR, and Beck J (1995) The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208:345-352.
12. Giacomini KM and Sugiyama Y (2006) Membrane transporters and drug response, in The Pharmacological Basis of Therapeutic, pp 41-70, McGraw-Hill, New York.
13. Giri N, Shaik N, Pan G, Terasaki T, Mukai C, Kitagaki S, Miyakoshi N, and Elmquist WF (2008) Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos 36:1476-1484.
14. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340. (Pubitemid 47121774)
15. Igel S, Drescher S, Mürdter T, Hofmann U, Heinkele G, Tegude H, Glaeser H, Brenner SS, Somogyi AA, Omari T, et al. (2007) Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin Pharmacokinet 46:777-785.
16. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649-15654.
17. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
18. Kalvass JC and Pollack GM (2007) Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24:265-276.
19. Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, and Schellens JH (2005) Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 55:72-78.
20. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
21. Mahony C, Wolfram KM, Nash PV, and Bjornsson TD (1983) Kinetics and metabolism of sulfinpyrazone. Clin Pharmacol Ther 33:491-497.
22. Matsson P, Pedersen JM, Norinder U, Bergström CA, and Artursson P (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816-1831.
23. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, and Prieto JG (2006) Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
24. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, and Schinkel AH (2005) The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758-1764. (Pubitemid 40594177)
25. Mimeault M, Hauke R, and Batra SK (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673-691.
26. Murakami T and Takano M (2008) Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4:923-939.
27. Ogihara T, Kamiya M, Ozawa M, Fujita T, Yamamoto A, Yamashita S, Ohnishi S, and Isomura Y (2006) What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. Drug Metab Pharmacokinet 21:238-244.
28. Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, and Schellens JH (2009) The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31-40.
29. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
30. Schellens JH, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, and Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73:1268-1271.
31. Seelig A and Landwojtowicz E (2000) Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31-40.
32. Skolnik S, Lin X, Wang J, Chen XH, He T, and Zhang B (2010) Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J Pharm Sci 99:3246-3265.
33. Stenberg P, Bergström CA, Luthman K, and Artursson P (2002) Theoretical predictions of drug absorption in drug discovery and development. Clin Pharmacokinet 41:877-899.
34. Troutman MD and Thakker DR (2003a) Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20:1210-1224.
35. Troutman MD and Thakker DR (2003b) Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20:1200-1209.
36. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, and Raevsky OA (1998) Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 6:151-165.
37. Varma MV, Sateesh K, and Panchagnula R (2005) Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm 2:12-21.
38. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
39. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, and Ware JA (2006) Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3:55-61.
40. Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, and Feng B (2009) The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos 37:946-955.